IGF-1 Longevity-Medicine Target Ranges: What the Evidence Actually Says

What Is IGF-1 and Why Does It Matter for Longevity?

IGF-1 is a 70-amino-acid peptide produced mainly in the liver in response to growth hormone (GH) pulses from the pituitary. It mediates most of GH's anabolic effects: muscle protein synthesis, bone turnover, and cellular repair. Because IGF-1 has a longer half-life (roughly 15 to 20 hours) than GH (minutes), it is the standard clinical proxy for GH axis activity. A single morning IGF-1 measurement reflects integrated 24-hour GH secretion far more reliably than a spot GH level.

IGF-1 and the Aging Axis

Serum IGF-1 peaks in mid-to-late adolescence, often reaching 300 to 500 ng/mL, and then declines at roughly 14% per decade. By age 60, most adults have IGF-1 levels in the 80 to 150 ng/mL range. This "somatopause" parallels age-related losses in lean mass, bone density, and exercise capacity. The Baltimore Longitudinal Study of Aging confirmed that lower IGF-1 in older adults independently predicts greater loss of muscle strength over a 5-year follow-up period.

IGF-1 vs. GH: Which Should You Measure?

GH is secreted in pulses, so a random blood draw may catch a near-zero trough or a peak. IGF-1 averages those fluctuations. For clinical titration of GH-releasing peptides, IGF-1 is the correct monitoring biomarker. GH stimulation testing (e.g., glucagon stimulation, macimorelin) is reserved for diagnosing adult GH deficiency (AGHD) when IGF-1 is low and pituitary pathology is suspected.

Standard Reference Ranges vs. Longevity-Medicine Targets

Standard lab reference ranges are population-derived and include everyone from sedentary, metabolically unhealthy individuals to elite athletes. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults recommends reporting IGF-1 as a standard deviation score (SDS) rather than an absolute ng/mL value, because age and sex produce large shifts in "normal." An SDS of 0 means exactly at the population median for your age and sex; an SDS of +1 means one standard deviation above the median.

Typical Lab Reference Ranges by Decade

| Age Range | Approximate IGF-1 Reference Interval (ng/mL) | |-----------|-----------------------------------------------| | 20 to 29 | 115 to 307 | | 30 to 39 | 109 to 284 | | 40 to 49 | 101 to 267 | | 50 to 59 | 94 to 252 | | 60 to 69 | 87 to 225 | | 70+ | 75 to 212 |

These intervals are illustrative of Quest Diagnostics and LabCorp age-banded norms. Always compare a patient's result to the specific assay's reference sheet, because immunoassay platforms differ.

Why Longevity Clinicians Use a Narrower Target

Longevity-medicine practitioners do not aim for the population median, which includes many sedentary or metabolically compromised adults. The working clinical consensus among GH-peptide prescribers targets 150 to 250 ng/mL regardless of the patient's chronological age. This range corresponds to the upper-normal zone of a healthy 30-to-40-year-old. The rationale: below 150 ng/mL, anabolic signaling (lean mass, bone) appears suboptimal; above 300 ng/mL, observational cancer-risk data become concerning. A 2012 meta-analysis in The Lancet Oncology (N=31 prospective studies) found that each standard deviation increase in IGF-1 above the population mean was associated with a 9% higher relative risk of colorectal cancer.

The 150 to 250 ng/mL target is therefore a clinical risk-benefit midpoint, not a number derived from a single randomized trial. It should be treated as a hypothesis to individualize, not a fixed prescription.

How GH-Releasing Peptides Affect IGF-1

GH secretagogues work by stimulating the pituitary's own GH release rather than replacing GH directly. Because they preserve pulsatile GH secretion, they carry a lower risk of supraphysiologic IGF-1 spikes compared to recombinant human GH (rhGH) injection.

Sermorelin

Sermorelin is a 29-amino-acid GHRH analogue. A randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=89 older adults) found that sermorelin 30 mcg/kg/day administered subcutaneously for 6 months raised IGF-1 by a mean of 48 ng/mL from a baseline of approximately 140 ng/mL. Sermorelin's FDA approval was withdrawn for commercial reasons in 2008 (not safety), and compounding pharmacies now supply it under 503B rules.

Tesamorelin

Tesamorelin (Egrifta) is the only FDA-approved GHRH analogue, indicated for HIV-associated lipodystrophy. The ERGO trial (N=412) demonstrated that tesamorelin 2 mg/day raised IGF-1 by roughly 73 ng/mL over 26 weeks and reduced visceral adipose tissue by 17.8% vs. Placebo. Mean end-of-study IGF-1 remained within the normal adult range in that trial, at approximately 195 ng/mL.

CJC-1295 and Ipamorelin

CJC-1295 is a long-acting GHRH analogue that, when combined with the GHRP ipamorelin, produces sustained GH and IGF-1 elevation. A pharmacokinetic study (N=21) showed CJC-1295 at 1 to 2 mg/kg raised IGF-1 by 28 to 39% above baseline and sustained that elevation for 6 to 14 days after a single injection. Neither CJC-1295 nor ipamorelin holds FDA approval; both are available through compounding. Clinical titration targets the same 150 to 250 ng/mL IGF-1 window used for sermorelin.

Recombinant Human GH (rhGH)

RhGH (somatropin, Genotropin, Norditropin) is approved for AGHD and several pediatric indications. Off-label use in "anti-aging" protocols is common but not FDA-sanctioned. IGF-1 rises more sharply with rhGH than with secretagogues because there is no pituitary feedback ceiling. Doses above 1 IU/day frequently push IGF-1 above 300 ng/mL in adults and require close monitoring. The Endocrine Society guideline states: "We recommend against the use of GH in healthy older people," citing lack of benefit in functional outcomes and potential for adverse effects including insulin resistance and fluid retention.

The IGF-1 and Cancer Risk Debate

The relationship between IGF-1 and cancer is the central controversy in longevity medicine. IGF-1 binds the IGF-1 receptor (IGF-1R), which activates PI3K/AKT/mTOR pathways that drive cell proliferation. The biology is plausible. The epidemiology is consistent but not definitive.

Key Observational Data

A prospective study published in Science (1998, N=152 cases vs. 152 matched controls) was among the first to show that men in the highest quartile of serum IGF-1 had a 4.3-fold higher risk of prostate cancer compared to men in the lowest quartile. This finding has been replicated in multiple cohorts, though effect sizes are smaller in more recent analyses.

A pooled analysis from the Endogenous Hormones and Breast Cancer Collaborative Group (N>14,000 cases) found that postmenopausal women in the highest quintile of IGF-1 had a 28% higher breast cancer risk than those in the lowest quintile. Premenopausal associations were weaker.

What Observational Data Cannot Tell Us

Observational IGF-1 cancer data measure endogenous, lifelong exposure. Iatrogenic IGF-1 elevation in a treated adult is different in timing, magnitude, and duration. No randomized controlled trial has been large enough or long enough to measure cancer incidence as an endpoint in adults receiving GH-peptide therapy. The Endocrine Society notes this gap explicitly. Clinicians must communicate this uncertainty to patients before initiating any GH-axis treatment.

The Longevity Paradox: Low IGF-1 in Centenarians

An equally important signal runs in the opposite direction. A study of Ashkenazi Jewish centenarians (N=384) found that a high proportion carried mutations in the IGF-1 receptor gene associated with lower IGF-1 signaling, and that low-normal IGF-1 correlated with exceptional longevity. Laron syndrome (IGF-1 receptor deficiency) is associated with virtual freedom from cancer despite elevated GH, supporting the hypothesis that it is IGF-1 receptor signaling rather than IGF-1 concentration alone that matters.

These opposing signals are why longevity clinicians argue for a moderate IGF-1 target rather than maximizing the level.

Interpreting a Low IGF-1 Result

Not every low IGF-1 requires treatment. Before attributing a low result to somatopause or GH deficiency, rule out the following confounders.

Common Causes of Suppressed IGF-1

Malnutrition and low caloric intake reduce hepatic IGF-1 production independently of GH. A study in the Journal of Clinical Endocrinology and Metabolism showed that a 5-day 50%-calorie-restricted fast reduced IGF-1 by 45% in healthy young men despite rising GH levels. This GH resistance of fasting is a clinically important confounder.

Hypothyroidism, poorly controlled type 1 diabetes, liver disease (cirrhosis), and chronic kidney disease all suppress IGF-1 production. The American Association of Clinical Endocrinologists (AACE) growth hormone deficiency guidelines recommend correcting thyroid and nutritional status before interpreting IGF-1 as a marker of GH axis function.

Estrogen therapy (oral route) suppresses IGF-1 by 20 to 30% relative to transdermal estrogen, a difference that has clinical implications for postmenopausal women on HRT who are also monitoring IGF-1.

When to Order GH Stimulation Testing

If IGF-1 is below the age-adjusted reference range AND the patient has risk factors for pituitary disease (prior cranial radiation, head trauma, pituitary adenoma history), formal GH stimulation testing is appropriate. The macimorelin stimulation test (Macrilen) holds FDA approval as a GH deficiency diagnostic and has replaced the insulin tolerance test in many U.S. Centers for safety reasons.

Monitoring IGF-1 During GH-Peptide Therapy

Baseline and Titration Schedule

Order a fasting morning IGF-1 before starting any GH secretagogue. Recheck at 6 to 8 weeks after initiation, then every 3 months during dose titration. Once the patient is stable in the 150 to 250 ng/mL range, annual monitoring is sufficient for most adults.

Dose Adjustment Principles

If IGF-1 exceeds 300 ng/mL, reduce dose. If it remains below 120 ng/mL after 12 weeks at the starting dose, consider whether poor adherence, caloric restriction, hypothyroidism, or oral estrogen are suppressing the response before increasing the secretagogue dose. A response above 300 ng/mL on a standard starting dose (e.g., sermorelin 200 mcg nightly) suggests high GH sensitivity and warrants a 25 to 50% dose reduction.

Other Labs to Check Concurrently

IGF-1 in isolation is insufficient. A complete GH-axis monitoring panel includes:

• Fasting glucose and HbA1c (GH is insulin-antagonizing; IGF-1 elevation may worsen insulin resistance)
• IGF-binding protein 3 (IGFBP-3), which modulates free IGF-1 bioavailability
• A lipid panel (tesamorelin reduces triglycerides, a secondary benefit worth tracking)
• Thyroid-stimulating hormone (TSH) to exclude hypothyroidism as an IGF-1 suppressor

A consensus statement from the Growth Hormone Research Society recommends monitoring IGF-1, glucose metabolism, and quality-of-life scores together as a triad of outcomes in adult GH deficiency treatment.

IGF-1 in Women: Sex-Specific Considerations

Women have lower IGF-1 than age-matched men throughout adulthood, a difference of roughly 20 to 30 ng/mL. Postmenopausal women on oral estrogen therapy may run 30 to 40 ng/mL lower than women on transdermal estrogen at equivalent systemic doses, because oral estrogen undergoes first-pass hepatic metabolism and suppresses IGF-1 production directly. Clinicians managing HRT and GH-peptide therapy together should switch to transdermal estrogen before concluding that the GH secretagogue is under-performing.

Pregnancy raises IGF-1 markedly (often to 300 to 500 ng/mL in the third trimester). GH-peptide protocols are contraindicated during pregnancy. Women of reproductive age require a negative pregnancy test before starting any GH secretagogue.

IGF-1 in Men on Testosterone Replacement Therapy

Testosterone (TRT) raises IGF-1 modestly. A study in the Journal of Clinical Endocrinology and Metabolism (N=52 hypogonadal men) found that testosterone enanthate 200 mg every 2 weeks for 6 months raised IGF-1 by a mean of 18 ng/mL from a baseline of 152 ng/mL. This means men on TRT who then add a GH secretagogue may reach the 150 to 250 ng/mL target at lower secretagogue doses than men not on TRT. Check IGF-1 after TRT optimization before layering in a peptide.